Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
April 26 2023 - 12:30PM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), a leading T-cell receptor (TCR) cell therapy company
advancing a clinical-stage pipeline of therapeutics for solid
tumors, today announced a poster presentation for its lead
non-viral Sleeping Beauty TCR-T cell therapy program in solid
tumors at the 2023 American Society of Clinical Oncology (ASCO)
Annual Meeting taking place June 2-6, 2023, at the McCormick Place
Convention Center in Chicago.
The TCR-T Library Phase 1/2 trial is an
open-label, dose-escalation trial being conducted at The University
of Texas MD Anderson Cancer Center. The trial is enrolling patients
with non-small cell lung, colorectal, endometrial, pancreatic,
ovarian and bile duct cancers that have a matching human leukocyte
antigen (HLA) whose tumors contain at least one of the targeted
driver mutations in KRAS, TP53 and EGFR.
Details of the poster presentation are as
follows:
Abstract Title: Safety and
Efficacy of Sleeping Beauty TCR-T Cells Targeting Shared KRAS and
TP53 Mutations Expressed by Solid Tumors in First-in-Human Phase 1
StudySession Title: Developmental
Therapeutics—ImmunotherapySession Date and Time:
Saturday, June 3, 8:00 a.m. - 11:00 a.m. CT Abstract
Number: 2547Presenter: Maria Pia Morelli,
M.D., Ph.D., Assistant Professor, Department of Gastrointestinal
Medical Oncology, Division of Cancer Medicine at MD Anderson
For more information, visit the ASCO Annual
Meeting website.
About Alaunos Therapeutics,
Inc.Alaunos Therapeutics is a leader in the science of
T-cell receptor (TCR) cell therapy working to revolutionize solid
cancer treatment and outcomes. The clinical-stage company’s TCR
T-cell therapy (TCR-T) is one of the most advanced TCR programs
targeting driver mutations in solid tumors with an ongoing Phase
1/2 trial of its TCR-T product candidates across six solid cancers.
Alaunos is powered by two proprietary platforms: its elegantly
efficient non-viral Sleeping Beauty cell engineering platform; and
its hunTR® discovery platform, which is expanding its
industry-leading library of TCRs against high-frequency driver
mutations. Alaunos is a part of an ongoing collaboration with the
National Cancer Institute (NCI), part of the National Institutes of
Health (NIH), working to advance the science of TCR therapy. For
more information, visit www.alaunos.com
Media Contact:Heather Anderson6
Degrees PRhanderson@6degreespr.com
Investor Contact:Alex LoboStern
Investor RelationsAlex.lobo@sternir.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Apr 2023 to Apr 2024